Bio-Techne Corporation
TECHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market capitalization of $7.79B, it sits in mid-cap territory. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Market Cap
$7.79B
Beta
1.41
P/E (TTM)
71.10
P/E (Fwd)
24.14
EPS (TTM)
$0.70
EPS (Fwd)
$2.06
ROE
5.3%
ROA
7.4%
Cash
$214.1M
Total Debt
$290.3M
Free CF
$299.8M
52W Change
-0.2%
Annual Financials
Cash vs Debt
Bio-Techne Corporation carries $290.3M in total debt against $214.1M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $299.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 5.3% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.11B to $1.22B.
At over 50x earnings, TECH carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bio-Techne Corporation's trajectory.